Income statement
CAD
Annual
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | -434 | -578 | -775 |
| Operating Income | -2M | -3M | -6M | -18M | -19M |
| EBITDA | -11M | -3M | -6M | -18M | -19M |
| Net Income | -11M | -6M | -6M | -18M | -20M |
| EPS (Diluted) | — | — | — | — | — |
Healthcare
Live Price
Offline$0.018
-10.00% today
1Y Change
+53.33%
Window
Jun 23, 2025 → Jun 12, 2026
Coverage: 245 bars · Jun 23, 2025 → Jun 12, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Revive Therapeutics Ltd. (RVVTF) is a Healthcare stock with a market cap of $10.00M and listed on OTC. The stock last traded around $0.02 and up 53.3% across the available one-year price window (Jun 23, 2025 → Jun 12, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of -102.7%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS -102.7%, free cash flow +76.7% with operating margin 0.0% and ROIC 36.6%. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines RVVTF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
RVVTF
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
RVVTF Max Drawdown
-61.54%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for RVVTF and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$0.0
FY Net Income
-$20.1M
-13.0% YoY
Free Cash Flow
-$11.3M
+13.4% YoY
Revenue Growth
+0.0%
EPS Growth
-102.7%
Gross Margin
0.0%
Net Margin
0.0%
Income statement
CAD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | -434 | -578 | -775 |
| Operating Income | -2M | -3M | -6M | -18M | -19M |
| EBITDA | -11M | -3M | -6M | -18M | -19M |
| Net Income | -11M | -6M | -6M | -18M | -20M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
CAD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 15K | 773K | 2M | 4M | 17M |
| Total Assets | 205K | 11M | 14M | 17M | 30M |
| Total Liabilities | 4M | 3M | 4M | 4M | 1000K |
| Shareholder Equity | -3M | 7M | 11M | 13M | 29M |
| Total Debt | 67K | 25K | 220K | 328K | 416K |
| Net Debt | 52K | -748K | -2M | -4M | -16M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
8M
+36.4% YoY
Capital Expenditures
3M
Free Cash Flow
11M
+13.4% YoY
Key ratios
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
899.6%
Debt / Equity
-0.02x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.